Methods: This retrospective observational study evaluated weight and BMI changes in aviremic HIV-infected patients who switched to an elvitegravir- or dolutegravir-containing regimen. Patients ≥18 years old on a stable ART regimen seen at the University of Utah Health Infectious Diseases Clinic between January 1, 2012 and February 28, 2017 who switched to an elvitegravir- or dolutegravir-containing regimen for at least 1 year were included. Exclusion criteria included patients with hypogonadism or a thyroid disorder, patients who received medications that impact weight (including steroids, levothyroxine, and metformin), and patients with 2 consecutive HIV viral load values >200 copies/mL during the study period. Body weight and BMI values collected prior to and approximately 1 year after the switch date were compared using paired t-tests.
Results: A total of 118 patients met study criteria and were included in the analysis. 88 (74.6%) patients were switched to a dolutegravir-containing regimen and 30 (25.4%) patients were switched to a regimen containing elvitegravir. Pre measurements were taken 5.9 (±13.3) days prior to the switch date (range: -83, +1 days), and post measurements were taken 310 (±56) days following the medication change (range: 186, 399 days). Weight increased on average 2.3 kg (95% CI: 1.6, 3; p<0.001), and BMI increased on average 0.8 kg/m2 (95% CI: 0.5, 1; p<0.001).
Conclusion: Aviremic patients with HIV gained an average of 2.3 kg approximately 310 days after switching to an elvitegravir- or dolutegravir-containing regimen. The average increase in BMI was 0.8 kg/m2. Weight gain may need to be included as a consideration when using an elvitegravir- or dolutegravir-containing regimen.
A. Presson, None
C. Jamjian, None